Pegfilgrastim biosimilar - Intas Biopharmaceuticals

Drug Profile

Pegfilgrastim biosimilar - Intas Biopharmaceuticals

Alternative Names: INTP 5; Lapelga; Neupeg; Pegasta; Recombinant pegylated granulocyte colony stimulating factor - Intas Biopharmaceuticals

Latest Information Update: 29 Aug 2016

Price : $50

At a glance

  • Originator Intas Biopharmaceuticals
  • Developer Apotex; Intas Biopharmaceuticals
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 29 Aug 2016 Intas Pharmaceuticals plans phase I study in healthy volunteers in India (CTRI/2016/07/007096)
  • 15 Mar 2016 Biomarkers information updated
  • 17 Dec 2014 Preregistration for Neutropenia in USA (SC) prior to 17 December 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top